Terminally Ill Patients’ Access To Experimental Medications Blocked By ‘Regulatory Schemes,’ Op-Ed Says
August 24th, 2007 by 
Barry - Admin BioPharmArena
The U.S. Court of Appeals for the District of Columbia issued a decision of “poor quality” on Tuesday when it ruled that terminally ill patients do not have the right to obtain access to unapproved prescription drugs that potentially are lifesaving, Roger Pilon, vice president for legal affairs at the Cato Institute and director of Cato’s Center for Constitutional Studies, writes in a Wall Street Journal opinion piece (Pilon, Wall Street Journal, 8/10).
In 2003, the Abigail Alliance for Better Access to Developmental Drugs and the Washington Legal Foundation filed a lawsuit against FDA to obtain access to experimental medications for terminally ill cancer patients. The lawsuit asked FDA to provide a special initial approval of experimental medications that appear effective and allow their sale and distribution to terminally ill patients who have no other approved treatment options.
Posted in News, Regulatory Affairs | 